FH is a genetic condition of very high cholesterol levels that presents a high risk for coronary artery disease.

Pediatric Familial Hypercholesterolemia The roots of ... was approved for children ages 10 and older with heterozygous and homozygous FH based on a trial showing a 38.3 percentage point greater ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Plasma exchange was first used to treat homozygous familial hypercholesterolemia (FH ... intermediate in heterozygous FH and fastest in subjects with normal LDL receptor function.

including heterozygous and homozygous familial hypercholesterolemia (HeFH / HoFH). About Lerodalcibep Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

adults living with heterozygous familial hypercholesterolemia (HeFH) and adults living with premature coronary artery disease (CAD). The Heart-2 clinical trial is expected to include four dose ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...